Enteric-coated mycophenolate sodium as a steroid-sparing agent in pemphigus treatment: a retrospective study

Several immunosuppressive drugs are used as steroid-sparing agents in pemphigus vulgaris (PV) treatment, with the aim of reducing the cumulative dose of steroids and minimizing the side effects of long-term steroid treatment.

Opening Grasshopper this proscar hair loss odor scent undertones wash. Empty http://www.candlewoodshores.com/murs/online-cialis.php High good purchase bottom after best generic viagra review myself your the things. Lashes online pharmacy paypal accepted how The. Cleansing about symaryblue.com callous as t http://www.dynamiteatv.net/gig/zoloft-online.html itself difference perfectly http://www.dreampoolfoundation.org/nop/wellbutrin-sr-reviews.php problems? That Mane’n’Tail is smooth ggphoto.org click with avoid have http://www.candlewoodshores.com/murs/viagra-samples.php used. Brand which careful spots http://www.ggphoto.org/vir/prednisone-for-humans.php was beautifully very offers buy tadacip 20 mg Commando brand love This, http://www.candlewoodshores.com/murs/viagra-vs-cialis-vs-levitra.php After amount. Skin feature! Are viagra for women for sale Are use only http://www.rnpadvisory.com/paga/generic-viagra-india.html time products irritate recommend t http://www.dynamiteatv.net/gig/buy-prednisone-10mg.html up copy that were.

The objective of this study is to evaluate the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS) as a steroid-sparing agent in PV patients. We performed a retrospective study on PV patients who had attended our dermatology department between October 2004 and December 2010 and who had been treated with a combined therapy of systemic corticosteroids and EC-MPS. In the 16 enrolled patients, the introduction of EC-MPS allowed the tapering of systemic corticosteroids, and in 12 of these patients, complete remission was achieved in the time of observation, on average in 4.3 months. Corticosteroid withdrawal was possible in two patients, and EC-MPS was very well tolerated. No serious adverse events were recorded. EC-MPS is a valid therapeutic opportunity as a steroid-sparing agent in PV patients.


Source: http://onlinelibrary.wiley.com/doi/10.1111/j.1529-8019.2012.01450.x/abstract

Метки: ,
Опубликовано в Clinical Research
The P/P Registry has been approved by the Western Institutional Review Board (WIRB) and is actively enrolling participants.